N/A N=120 Urology San Antonio MRI/MicroUS Comparison
Prostate Cancer
Primary: Number of Participants With Clinically Significant Cancer — 38; 31 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=71 The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study
Carcinoma, Transitional Cell · Transitional Cell Carcinoma of Renal Pelvis
Primary: The Primary Efficacy Endpoint Was the Number of Patients Attaining Complete Response (CR) at the End of the Treatment Period (PDE Visit). — 42 Participants
N/A N=3 HYbrid RObotic Surgery in Urology
Nephrectomy
Primary: Safety of the Bitrack System — 0; 0 adverse events
N/A N=12 Urodynamic Feasibility Study Utilizing the UroLift® System
Benign Prostatic Hyperplasia
Primary: Qmax Assessed Using Urodynamic Testing (Cystometry) — 14.0 mL/sec
Phase 4 N=512 Tamsulosin for Urolithiasis in the Emergency Dept
Ureterolithiases
Primary: Proportion of Patients Passing Their Stone Within 28 Days by Self Report — 128; 113 Participants
Phase 4 N=630 Value of Urodynamic Evaluation
Urinary Incontinence
Primary: Self-reported Urinary Incontinence, Irritative and Obstructive Symptoms: Reduction of 70%+ in the Urogenital Distress Inventory From Baseline to 12 Mos and "Very Much"…
Phase 4 N=610 Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery
Post-operative Urinary Retention
Primary: Number of Patients Who Undergo Postoperative Catheterization for Urinary Retention — 23; 25 Participants — p=.96
N/A N=108 Trial Assessing Renal Damage During Ureteroscopy
Nephrolithiasis
Primary: Change in Kidney Injury Molecule-1 (KIM-1) — 0.01077; 0.01228; 0.0246; 0.02413 ng/ml
N/A N=9 Urology of Virginia Case Series
Prostate Cancer · Cancer of the PROSTATE · Prostatic Neoplasm
Primary: Keyword Description of Each Biopsy Sample — 89 percentage significant cancers detected
N/A N=45 Study of Median Lobe Prostatic UroLift Procedure
Benign Prostatic Hyperplasia (BPH)
Primary: At 6 Months, the 95% Lower Confidence Limit of the Mean Percent Improvement in IPSS Over Baseline for the UroLift System Must be ≥ 25%. — 57.7 percent change
N/A N=51 UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Benign Prostatic Hyperplasia
Primary: Quality of Recovery — 28; 16 participants
N/A N=170 Real World Data on Management of Male LUTS
Benign Prostatic Hyperplasia
Primary: The Percentage of Men Given a Drug Prescription for Their Urinary Symptoms, as Recorded in Their Medical Records — 35.7 Percentage of participants
N/A N=46 Effects of Flexible Ureteroscopy on Renal Blood Flow
Circulatory; Change
Primary: Peak Systolic Velocities (PSV) Measurement by Renal Doppler Ultrasound (US) Examination Evaluating the Effects of Flexible Ureteroscopy (F-URS) on Renal Blood Flow by…
N/A N=12 Uroflow Measurements in Healthy Volunteers
Healthy
Primary: Voided Volume — 306 mL
N/A N=525 Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists
Urologic Diseases · Antibacterial Drug Adverse Reaction
Primary: Percentage of Cases Who Received Excessive Post-procedural Antimicrobials — 216; 644 Participants — p=0.004
Phase 4 N=27 A Randomised Cross-over Study With Two 1-piece Urostomy Bags.
Urostomy
Primary: Preference of Sensura vs Moderma — 45; 43 percentage of prefering the product
N/A N=80 BPH-6: Comparison of the UroLift System to TURP for Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Responder Analysis: A Subject is a Responder at the 12 Month Follow-up Time Point if All 6 Thresholds of the BPH-6 Endpoint Are Met — 52; 20 % Responders of Participants
N/A N=150 The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
Overactive Bladder · Urinary Incontinence · Urinary Frequency or Urgency Adverse Event
Primary: Day Urinary Frequency — 7.68; 10.95 number of diurnal micturitions per day
N/A N=100 Medical Expulsive Therapy of Single Distal Ureteral Stones
Ureteral Calculi
Primary: Number of Participants With Stone Expulsion — 39; 40 Participants
N/A N=74 The Predictive Value of Ureteral Jet Assessment With Ultrasound in Patients Presenting With Acute Renal Colic
Ureteral Calculi
Primary: Time in Days From Diagnosis to Stone Passage. — 5; 13 Days
N/A N=150 Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Urinary Incontinence · Prostate Cancer
Primary: Number of Continent Patients Post Prostatectomy — 37; 32 participants
Phase 4 N=2,776 Study of Tomography of Nephrolithiasis Evaluation
Urolithiasis
Primary: High Risk Diagnosis With Complication — 6; 3; 2 participants
N/A N=45 BULLET: Bladder Ultrasound Limits Length (of Time), Expedites Treatment
Point-of-Care Bladder Ultrasound · Urethral Catheter
Primary: Time to Successful Completion of Pelvic Ultrasound — 103.95; 92.82 minutes
Phase 4 N=136 Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures
Urinary Tract Diseases
Primary: Total Opioid Consumption — 16.4; 15.3 morphine equivalent
Phase 4 N=181 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction
Ureteral Obstruction
Primary: Ureteral Stent Symptom Questionnaire Score Up to 24 Hours Prior to Stent Insertion — 1.76; 1.84; 2.02; 1.93 score on a scale
Phase 2 N=239 Study of Silodosin to Facilitate Passage of Urinary Stones
Ureteral Calculi · Kidney Stones · Urolithiasis
Primary: Spontaneous Stone Passage (Distal Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures…
N/A N=42 Uro-NIRS Clinical Study
Lower Urinary Tract Symptoms · Overactive Bladder
Primary: Number of Participants Reporting Downward/Flat/Upward Patterns as Assessed by Near Infrared Spectroscopy (NIRS) for BOO Diagnosis — 9; 4; 13; 4 participants
N/A N=84 Treatment for Acute Postoperative Voiding Dysfunction
Urinary Retention
Primary: Persistent Retention — 29; 21 participants
N/A N=95 Impact Ureteral Sheath Design During Ureteroscopy
Renal Stone · Nephrolithiasis · Urolithiasis
Primary: Number of Participants With Successful Sheath Placement — 37; 39 Participants
Phase 3 N=104 The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms
Disorder of Urinary Stent
Primary: Lower Urinary Tract Symptoms (LUTS) — 11.12; 4.39; 7.21; 5.58 units on a scale